Clinical trial · Observational
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ablation of Celiac Ganglion | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Unresectable Pancreatic Cancer
- description
- Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
- interventionNames
- Procedure: Ablation of Celiac Ganglion
Primary outcomes (7)
- measure
- Pain severity-BPI
- timeFrame
- From Baseline up to 3 Months
- description
- Change in severity of pain will be assessed using a standardized the Brief Pain Inventory-Short Form (BPI) ranging from 0 (no pain) to 10 (worst pain possible).
- measure
- Pain severity-VAS
- timeFrame
- From Baseline up to 3 Months
- description
- Change in severity of pain will be assessed using visual analog scale (VAS) ranging from 0 (no pain) to 10 (worst pain possible).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of pancreatic cancer based on clinical, radiological, or pathological assessment; * Referred for abdominal and/or back pain due to pancreatic cancer; * No prior history of RFA; * Cancer pain unresponsive to the WHO 3-step analgesic ladder; * Willingness to consent to participate in the study. Exclusion Criteria: * Patients who are not willing to give informed consent or agree to participate in the study * Surgically resectable pancreatic cancer; * Abdominal pain with etiology other than pancreatic malignancy; * Evidence of concurrent infection; * Patients with irreversible coagulopathy international normalized ratio \>1.5 or platelet count \<50,000/mm3), * Patients with a preliminary diagnosis of adenocarcinoma are not possible established with intraprocedural at EUS-guided FNA.
References
Publications (0)
Data not yet available